ReviewIndian journal of ophthalmology2026
Home monitoring devices for glaucoma.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is a leading cause of irreversible blindness worldwide, with global prevalence projected to rise substantially in the coming decades. Advances in digital health technology have enabled the development of home-based monitoring devices that support patient-centered care. This review provides a comprehensive overview of current and emerging technologies for home glaucoma monitoring, focusing on intraocular pressure (IOP) assessment, optic disc imaging, and visual field testing. Home tonometry includes rebound devices such as the iCare HOME rebound tonometer and Tap Eye tonometer. Continuous IOP monitoring approaches include contact lens sensors (CLSs) such as Triggerfish CLS, miLens microfludic CLS, and implantable telemetric systems including Eyemate-IO and Eyemate-SC, offering insights into diurnal IOP fluctuations. IOP Connect (Injectsense) is a miniature implant that records and wirelessly uploads IOP data, though long-term validation is pending. Q Smart (Qura) is a remotely powered suprachoroidal sensor with frequent measurements, currently supported only by animal data. Smartphone-based optic disc imaging and devices with smartphone adapters provide accessible structural assessment, though image quality and user dependence remain limitations. Home-based perimetry platforms such as Melbourne rapid fields, Peristat, Eyeonic online circular-contrast perimetry, VisuALL, C3 Field Analyzer, Mobile virtual perimetry-Frequency-doubling technology, and Eyecatcher 3.0 show good agreement with standard automated perimetry while enhancing accessibility and testing frequency. Although these technologies show considerable potential to enhance disease surveillance and patient engagement, barriers including cost, regulatory approval, long-term validation, and integration into clinical work flows persist. Large-scale studies and unified digital platforms integrating structural and functional data are required to establish their role in routine glaucoma care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.